[The HIV infection rate is 0! The effectiveness of the preventive drug Lenacapavir will be finally determined. The scale of long-term treatment will take off in 2031 or reach 36.7 billion yuan.] On June 20, local time, Gilead Science, an American biopharmaceutical company, announced on its official website that its Lenacapavir research and development showed 100% effectiveness in the pre exposure prevention (PrEP) of HIV (HIV), which is the first phase III HIV prevention test with zero infection in history. Affected by this, Gilead closed up 8.48% on the same day, reaching its highest level since early April, and continued to rise by 3.18% the next day. This week, the company's stock price has risen by 12.5% to $70.67 per share, and its market value has risen by $7.973 billion to $88.044 billion.